IntegraGen in the news

A court decision on IntegraGen's future is expected on October 9, 2026, following takeover bids that could lead to liquidation and delisting.

IntegraGen faces judicial liquidation and delisting from Euronext Growth Paris following offers to acquire its assets but not shares, which will be used to pay creditors, leaving shareholders at risk of losing their investment.

IntegraGen is awaiting a court decision on October 9 regarding acquisition offers from ABL Diagnostics and Health In Code for its assets, following a judicial recovery procedure.

A court decision is anticipated on October 9 concerning acquisition bids from ABL Diagnostics and Health In Code for IntegraGen's assets, which will lead to the company's liquidation and delisting.

IntegraGen, a French genomics company, faces judicial liquidation, with its assets and activities subject to takeover bids from ABL Diagnostics and Health In Code, as the court prepares its ruling on October 9, 2026.

IntegraGen, a genomics company, is awaiting a court decision on October 9, 2026, regarding two takeover bids from ABL Diagnostics and Health In Code, with potential implications for shareholders.

IntegraGen's judicial recovery proceeding for potential takeover bids does not include share repurchases, risking total loss for shareholders, with a court decision expected on October 9, 2026.

Several companies are making significant business moves, with Novo Nordisk rebranding, Ipsen considering a US plant, IntegraGen facing takeover bids, Maat Pharma's drug rejected, and Biomunex entering Phase I trials.

IntegraGen, a genomics company in judicial recovery, has received two takeover bids from Health In Code and ABL Diagnostics for its assets and activities.

Biotechnology company IntegraGen received two takeover offers from Health In Code and ABL Diagnostics as part of its receivership proceedings.

IntegraGen, a genomics company in receivership, has received two takeover bids from Health In Code and ABL Diagnostics, with a court decision expected in October 2026.

Two confidential takeover bids have been submitted for IntegraGen's assets, potentially leading to delisting and no shareholder value.

IntegraGen, a genomics company in receivership, has received two takeover bids from Health In Code and ABL Diagnostics, but shareholders face a total loss of investment.

ABL Diagnostics has submitted a takeover offer for IntegraGen, pending court approval, as part of its external growth strategy.

IntegraGen received two takeover bids from Health In Code and ABL Diagnostics as part of its court-ordered receivership, with no guarantee of value for shareholders.

IntegraGen, a genomics company, received two takeover bids for its assets and activities from Health In Code and ABL Diagnostics, with shareholders facing potential total loss as a court decision looms.

ABL Diagnostics has made an offer to acquire IntegraGen's business and assets, pending court approval.

Integragen, under judicial receivership, has received two takeover bids from Health In Code and ABL Diagnostics for its activities and assets, with a court decision expected by October 5, 2026.

IntegraGen received two takeover bids for its assets and activities from Health In Code and ABL Diagnostics as part of its judicial reorganization, with shareholders facing a risk of total loss.

IntegraGen, a biotechnology company, has received two takeover bids from Health In Code and ABL Diagnostics as part of a judicial reorganization.